Correction: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics

Gunjan D Hariani1, Ernest T Lam3, Tammy Havener4, Pui-Yan Kwok3, Howard L McLeod4,5, Michael J Wagner4 and Alison A Motsinger-Reif1,2*

Correction

After publication of this work [1], it has come to our attention that there is an error in the author list of the initial version of this manuscript; rather than Ernest J Lam, the second author of the manuscript should be listed as Ernest T Lam.

We publish this correction to update the author list with this information. The correct author list is as follows:

Gunjan D Hariani, Ernest T Lam, Tammy Havener, Pui-Yan Kwok, Howard L McLeod, Michael J Wagner and Alison A Motsinger-Reif

This error was introduced during the final production process and the editors of BMC Research Notes apologise for any inconvenience caused.

Author details
1Bioinformatics Research Center, North Carolina State University, 307 Ricks Hall, 1 Lampe Dr, 27695 CB7566 Raleigh, NC, USA. 2Department of Statistics, North Carolina State University, Raleigh, NC, USA. 3Cardiovascular Research Institute, UCSF School of Medicine, San Francisco, CA, USA. 4Center for Institute of Pharmacogenomics and Individualized Therapy, UNC Chapel Hill, Chapel Hill, NC, USA. 5Moffitt Cancer Center, Tampa, FL, USA.

Received: 9 September 2014 Accepted: 10 September 2014 Published: 17 September 2014

Reference

doi:10.1186/1756-0500-7-652
Cite this article as: Hariani et al.: Correction: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Research Notes 2014 7:652.